Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Neuropharmacol ; 47(3): 82-86, 2024.
Article in English | MEDLINE | ID: mdl-38743601

ABSTRACT

OBJECTIVE: This trial analyzed high-sensitivity C-reactive protein (hs-CRP), homocysteine (Hcy), and macrophage migration inhibitory factor (MIF) level in serum and their correlation with symptom severity and cognitive function in patients with schizophrenia (SP). METHODS: Sixty-eight SP patients were enrolled in the SP group, and 68 healthy volunteers were in the control (CN) group. Serum hs-CRP, Hcy, and MIF were measured, and symptom severity was assessed with the Positive and Negative Symptom Scale (PANSS). Cognitive function was determined with the MATRICS Consensus Cognitive Battery (MCCB). The SP group was divided into high PANSS score (PANSS ≥70 points) and low PANSS score (PANSS <70 points), or the mild cognitive dysfunction group and severe cognitive dysfunction group according to the median MCCB score. The correlation between serum hs-CRP, Hcy, and MIF levels and PANSS and MCCB scores in SP patients was examined by Pearson correlation analysis. RESULTS: SP patients had higher serum hs-CRP, Hcy, and MIF levels and showed higher PANSS scores and lower MCCB total score. Serum hs-CRP, Hcy, and MIF levels in the high PANSS group were higher than those in the low PANSS group and in the severe cognitive dysfunction group than in the mild cognitive dysfunction group. Serum hs-CRP, Hcy, and MIF levels in SP patients were positively correlated with PANSS total score and negatively correlated with MCCB total score. CONCLUSION: High serum hs-CRP, Hcy, and MIF levels in SP patients are correlated with symptom severity and cognitive dysfunction.


Subject(s)
C-Reactive Protein , Homocysteine , Macrophage Migration-Inhibitory Factors , Schizophrenia , Humans , Macrophage Migration-Inhibitory Factors/blood , Male , Female , Homocysteine/blood , Schizophrenia/blood , Schizophrenia/complications , C-Reactive Protein/analysis , Adult , Middle Aged , Severity of Illness Index , Cognitive Dysfunction/blood , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/etiology , Cognition/physiology , Intramolecular Oxidoreductases/blood , Psychiatric Status Rating Scales , Biomarkers/blood , Schizophrenic Psychology , Neuropsychological Tests
2.
PLoS One ; 16(4): e0249997, 2021.
Article in English | MEDLINE | ID: mdl-33914752

ABSTRACT

Second-generation antipsychotics (SGAs) play a critical role in current treatment of schizophrenia (SCZ). It has been observed that sinus bradycardia, rare but in certain situations life threatening adverse drug reaction, can be induced by SGAs across different schizophrenia populations. However, the roles of genetic factors in this phenomenon have not been studied yet. In the present study, a genome-wide association study of single nucleotide polymorphisms (SNPs) was performed on Chinese Han SCZ patients to identify susceptibility loci that were associated with sinus bradycardia induced by SGAs. This study applied microarray to obtain genotype profiles of 88 Han Chinese SCZ patients. Our results found that there were no SNPs had genome-wide significant association with sinus bradycardia induced by SGAs. The top GWAS hit located in gene KIAA0247, which mainly regulated by the tumor suppressor P53 and thus plays a role in carcinogenesis based on resent research and it should not be a susceptibility locus to sinus bradycardia induced by SGAs. Using gene-set functional analysis, we tested that if top 500 SNPs mapped genes were relevant to sinus bradycardia. The result of gene prioritization analysis showed CTNNA3 was strongly correlated with sinus bradycardia, hinting it was a susceptibility gene of this ADR. Our study provides a preliminary study of genetic variants associated with sinus bradycardia induced by SGAs in Han Chinese SCZ patients. The discovery of a possible susceptibility gene shed light on further study of this adverse drug reaction in Han Chinese SCZ patients.


Subject(s)
Antipsychotic Agents/adverse effects , Bradycardia/etiology , Genome-Wide Association Study , Schizophrenia/genetics , Adult , Antipsychotic Agents/therapeutic use , Bradycardia/genetics , China , Female , Genotype , Humans , Male , Membrane Proteins/genetics , Middle Aged , Polymorphism, Single Nucleotide , Protein Interaction Maps/genetics , Schizophrenia/drug therapy , Schizophrenia/pathology , Tumor Suppressor Protein p53/metabolism , alpha Catenin/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...